"当前创新药销售费用中，基本医保承担44%，商业保险承担7%，其余近半数需由患者自费或通过其他 途径解决。"国家医疗保障局医药管理司司长黄心宇在医保目录解读会上公布的这组数据，直指创新药 支付端的现实痛点。 2026年以来，创新药产业迎来政策密集赋能，支付体系优化与药品可及性提升的双重利好同步落地，国 家打通创新药落地"最后一公里"的力度空前。1月1日，2025年新版国家医保药品目录与首版商保创新药 目录在全国正式实施；1月22日，商务部等9部门联合印发《关于促进药品零售行业高质量发展的意 见》，明确鼓励创新药、参比制剂等进入零售药店销售渠道。一系列新政落地，正从支付、渠道等多维 度重构创新药行业生态，为产业发展注入全新动力。 一次规模扩容 2025年新版国家医保药品目录的调整，堪称医保目录诞生以来创新药规模最大的一次扩容。黄心宇介 绍，本次目录新增114种药品，同步调出29种临床无供应或可被更好替代的药品，新增药品111种为5年 内新上市品种、50种为I类新药，数量与占比均创历年新高。 此次新增的医保药品，均具备填补临床空白、同类疗效更优、性价比突出三大核心特征，精准对接临床 未满足的治疗需求。黄心宇说：" ...

Core Insights - The article discusses the competitive landscape of the IL-4Rα monoclonal antibody market, highlighting Dupixent's dominance and the emerging challenges from new entrants [2][11][15] Group 1: Dupixent's Market Position - Dupixent, developed by Sanofi, has achieved significant sales milestones, with Q4 2025 revenue reaching €4.246 billion (approximately $5.085 billion), marking a 32.2% year-over-year increase [1] - Since its FDA approval in March 2017, Dupixent has rapidly become a leading drug in the autoimmune space, with sales surpassing $2.2 billion in its first year and exceeding $2 billion in 2019 [3][5] - The drug's success is attributed to its strategic targeting of the IL-4Rα pathway, which is crucial in mediating type 2 inflammation, and its innovative VelocImmune® technology that enhances safety and efficacy [6][7] Group 2: Competitive Landscape - The approval of Connoa's Suplizumab in September 2024 marks the second IL-4Rα monoclonal antibody to enter the market, intensifying competition against Dupixent [12] - Other candidates, including Leideqi (CBP-201) and Tairiqi, are in the NDA stage, indicating a growing pipeline of competitors that could challenge Dupixent's market share [13][14] - The emergence of these new IL-4Rα monoclonal antibodies suggests a shift from a "one-player" market to a more competitive environment, with multiple players vying for market share [11][15] Group 3: Future Outlook - The article suggests that while Dupixent remains a strong player, its growth may face challenges due to the increasing number of competitors and the saturation of its core indications [15] - The competitive dynamics in the IL-4Rα space are expected to evolve, with a focus on differentiation strategies and the expansion of indications being critical for maintaining market position [15]

Core Insights - The new national medical insurance drug list and the first commercial insurance innovative drug list will be implemented nationwide starting January 1, 2026, marking the largest expansion of innovative drugs in the history of the medical insurance directory [1] - The adjustment of the medical insurance directory represents a dual benefit for the innovative drug industry in China, with significant changes in the inclusion of innovative drugs and the establishment of a commercial insurance innovative drug directory [1][2] Summary by Sections Innovative Drug Inclusion - A total of 114 new drugs have been added to the national medical insurance drug list, including 111 new products launched within the last five years and 50 Class I new drugs, both of which set historical highs in terms of quantity and proportion [1][2] - The newly included drugs generally possess three common characteristics: they either fill a treatment gap, are superior alternatives, or offer better cost-effectiveness [2] Commercial Insurance Innovative Drug Directory - The first commercial insurance innovative drug directory includes 19 drugs, covering treatments for various conditions such as CAR-T therapies for tumors, rare diseases like Gaucher disease, and Alzheimer's disease, complementing the basic medical insurance [2][3] - The selection mechanism for the commercial insurance directory emphasizes high innovation, significant clinical value, strong irreplaceability, and adaptability to a multi-tiered payment system [3] Payment System and Market Impact - The medical insurance fund has paid over 460 billion yuan for negotiated drugs by the end of October 2025, benefiting 1 billion patients and driving related drug sales exceeding 670 billion yuan [4] - The new dual-directory system aims to clarify the boundaries of basic medical insurance coverage while allowing space for commercial insurance development, thus supporting a multi-tiered payment system [3][4] Innovation Ecosystem - The integration of the commercial insurance innovative drug directory with the national medical insurance drug list is crucial for building a multi-layered medical security system, focusing on high-innovation and clinically significant drugs that exceed basic insurance coverage [5] - The successful inclusion of breakthrough therapies like Alpelisib not only provides hope for patients but also signals strong support for genuine innovation within the pharmaceutical industry [5]

Investment Rating - The report does not explicitly state an investment rating for the interleukin industry Core Insights - The interleukin family consists of various cytokines that play significant roles in immune regulation, inflammation, and cancer, with many related drugs and clinical pipelines in development [4][5] - The IL-12 and IL-23 cytokines are crucial in immune modulation and have become important therapeutic targets for autoimmune diseases such as psoriasis and Crohn's disease [9][10] - The market for IL-4Rα drugs in allergic diseases is expanding, with two main drugs approved in China for treating allergic asthma and other conditions [16] - IL-1β inhibitors are gaining traction in gout treatment, with a notable increase in patient numbers projected for high uric acid levels and gout by 2030 [23][25] - Artificial intelligence is enhancing drug development processes across various stages, significantly reducing the time required for drug discovery and optimization [31][32] Summary by Sections Interleukin Family Overview - The interleukin family includes multiple members categorized into several groups, each with distinct roles in immune response and disease [3][4] - Key interleukins such as IL-1, IL-2, IL-6, IL-10, and IL-17 are involved in autoimmune and inflammatory diseases, with existing drugs and clinical pipelines targeting these cytokines [5] Market Status of IL-12/IL-23 - Several drugs targeting IL-12 and IL-23 have been approved for treating autoimmune diseases, with notable examples including Ustekinumab and Guselkumab [8][10] - The first fully human monoclonal antibody targeting IL-12/IL-23, Iroquois, is set to launch in 2025 for moderate to severe plaque psoriasis [10] IL-4 in Allergic Diseases - Two IL-4Rα drugs have been approved in China for allergic diseases, with Dupilumab included in the national medical insurance list [16] - The report outlines ongoing clinical trials for additional IL-4Rα therapies targeting various allergic conditions [17] IL-1β Inhibitors in Gout Treatment - The report highlights the increasing prevalence of high uric acid and gout, with projections indicating significant growth in patient numbers by 2030 [21][23] - The first IL-1β monoclonal antibody, Canakinumab, has been approved for gout treatment, with a projected global sales figure of $1.5 billion by 2024 [25] Role of Artificial Intelligence in Drug Development - AI is transforming drug discovery by streamlining processes and improving efficiency, reducing the time for lead compound optimization from approximately 65 months to 30 months [32] - The integration of AI in drug development enhances the accuracy of personalized medicine and accelerates the identification of effective drug candidates [31][32]

Core Viewpoint - Guojin Securities has initiated coverage on Connoa-B with a "Buy" rating and a target price of HKD 83.29, highlighting the company's strategic focus on differentiated self-immune chronic disease and oncology sectors [1] Company Overview - Connoa-B has a robust pipeline with multiple ongoing clinical trials, including the core product, Supichibai monoclonal antibody, which has already been approved for market [1] - The CM512 (TSLP/IL-13 dual antibody) is currently expanding into several Phase II clinical trials, while the licensed CMG901 is expected to submit an NDA in the U.S. by 2026 [1] Product Insights - Supichibai monoclonal antibody is the first domestically produced IL-4R monoclonal antibody, providing a significant first-mover advantage [1] - Following the implementation of medical insurance in 2026, the product is anticipated to experience rapid market growth [1] Market Potential - The IL-4R monoclonal antibody targets various type II inflammatory diseases, including atopic dermatitis (AD) and chronic rhinosinusitis with nasal polyps (CRSwNP) [1] - Currently, only two IL-4R monoclonal antibodies have been approved globally, with Sanofi's Dupilumab achieving rapid market penetration since its launch in 2017, and projected global sales exceeding USD 14 billion in 2024 [1]

Core Viewpoint - The report from Guojin Securities highlights the promising pipeline of Connoa-B (02162), with its core product, Supacibab, already approved for market. The company is expanding its clinical trials for CM512 (TSLP/IL-13 bispecific antibody) and expects to submit an NDA for CMG901 in the U.S. by 2026. The company has a robust pipeline and is well-positioned for growth, receiving a "Buy" rating with a target price of HKD 83.29 [1]. Group 1: Product Pipeline and Market Potential - Supacibab is the first domestically produced IL-4R monoclonal antibody, providing a significant first-mover advantage. It targets various type II inflammatory diseases, with expectations for rapid market uptake post-2026 when it enters the national medical insurance directory [1]. - The global sales of Dupilumab, a competing IL-4R monoclonal antibody, exceeded USD 14 billion in 2024, indicating a strong market potential for Supacibab, which has already been approved for three indications [1]. - Sales projections for Supacibab are estimated at CNY 0.36 billion in 2024, CNY 1.69 billion in the first half of 2025, and expected to reach CNY 3.31 billion, CNY 9.05 billion, and CNY 16.27 billion from 2025 to 2027 [1]. Group 2: Clinical Development and Competitive Landscape - CM512 is currently in Phase II clinical trials and is positioned as the second globally in development, with significant differentiation advantages in the respiratory market. It targets asthma and COPD, with potential approval by 2029 [2]. - CMG901, a Claudin 18.2 ADC, has been licensed to AstraZeneca and is the fastest progressing globally. It is expected to complete Phase III trials for second-line gastric cancer by 2026 and submit for market approval, with potential milestone payments and royalties for the company [2]. Group 3: Financial Projections and Valuation - The company is projected to achieve revenues of CNY 6.61 billion, CNY 12.55 billion, and CNY 20.64 billion for the years 2025, 2026, and 2027, reflecting year-on-year growth rates of 54%, 90%, and 65% respectively [3]. - The net profit forecast shows a loss of CNY 5.13 billion in 2025, narrowing to a loss of CNY 2.97 billion in 2026, before turning to a profit of CNY 2.01 billion in 2027, with corresponding EPS of -1.72, -0.99, and 0.67 [3]. - A DCF valuation method has been applied, resulting in a target price of HKD 83.29, with an initial "Buy" rating assigned [3].

Core Viewpoint - The report from Guojin Securities highlights the promising pipeline of Connoa-B (02162), with its core product, Supqi Baidankang, already approved for market release. The company is advancing multiple Phase II clinical trials for CM512 (TSLP/IL-13 bispecific antibody) and expects to submit an NDA for CMG901 to the FDA by 2026, indicating a strong growth potential and robust pipeline [1]. Group 1: Product Pipeline and Market Potential - Supqi Baidankang is the first domestically produced IL-4R monoclonal antibody, which is expected to gain rapid market traction after being included in the national medical insurance directory by December 2025, with anticipated sales of 0.36 million, 1.69 million, 3.31 million, 9.05 million, and 16.27 million yuan from 2024 to 2027 [1][3]. - CM512 (TSLP/IL-13 bispecific antibody) is currently in Phase II clinical trials and is positioned as the second globally in development, targeting a broad respiratory market with significant potential, expected to be approved by 2029 [2]. - CMG901 (Claudin 18.2 ADC) has been licensed to AstraZeneca and is the fastest progressing globally, with expectations to complete Phase III clinical trials for second-line gastric cancer by 2026 and potentially launch in 2027, which could yield milestone revenues and royalties for the company [2]. Group 2: Financial Projections and Valuation - The company is projected to achieve revenues of 661 million, 1.255 billion, and 2.064 billion yuan for the years 2025, 2026, and 2027, reflecting year-on-year growth rates of 54%, 90%, and 65% respectively, with a turnaround to profitability expected in 2027 [3]. - The estimated earnings per share (EPS) are projected to be -1.72, -0.99, and 0.67 yuan for the years 2025, 2026, and 2027, indicating a path towards profitability [3]. - Based on a DCF valuation method, the target price is set at 83.29 HKD, with an initial "buy" rating assigned [3].

Core Viewpoint - The probability of IPO failure for companies like Maijizhi Bio, which have not yet entered the hearing stage after submitting their applications to the Hong Kong Stock Exchange, is increasing, with the company expressing concerns about the successful development and commercialization of its core product MG-K10 [1][4]. Company Overview - Maijizhi Bio, established in 2016, focuses on clinical-stage biopharmaceuticals for allergic and autoimmune diseases, with a pipeline of eight innovative candidates, the most advanced being the long-acting anti-IL-4Rα antibody MG-K10 [2][4]. - The company has partnered with Kangzhe Pharmaceutical, granting them exclusive commercialization rights for MG-K10, which reflects Maijizhi Bio's challenges in independently navigating a competitive market [2]. Market Potential - The global market for atopic dermatitis drugs is projected to grow from $14.2 billion in 2023 to $29.1 billion by 2032, with the Chinese market expected to increase from 8.4 billion RMB to 46.4 billion RMB [3]. - The IL-4Rα space in China is highly competitive, with multiple companies, including Sanofi and Kangzhe, already having products on the market or in advanced clinical stages [3]. Intellectual Property Challenges - Maijizhi Bio faces significant intellectual property challenges, particularly from its former parent company, Sanofi, which has initiated legal actions regarding patents related to MG-K10 [5][6]. - The company has previously lost a patent dispute to Sanofi, which raises concerns about the stability of its core patents and the potential impact on MG-K10's commercialization [7]. Financial Situation - Since its inception, Maijizhi Bio has operated without product revenue, relying on financing to sustain operations, with reported revenues of 8.72 million RMB, 24,000 RMB, and 0 RMB for 2023 and the first quarter of 2025 [8][9]. - The company has incurred significant losses, with net losses of 253 million RMB, 178 million RMB, and 27 million RMB for the same periods, and a cumulative loss exceeding 808 million RMB as of March 2025 [9]. - Cash flow is a critical concern, with only 70.78 million RMB in cash and equivalents as of March 31, 2025, and estimated costs of 500 to 600 million RMB needed to complete clinical trials and registration for MG-K10 [9]. Financing and Investment - Maijizhi Bio has successfully raised over 700 million RMB through multiple financing rounds since its establishment, achieving a post-investment valuation of 2.64 billion RMB after the Pre-IPO round in 2025 [10]. - Some early investors have begun to exit, with significant share transfers occurring prior to the company's IPO application, indicating potential investor concerns about the company's future [10].

Group 1 - The autoimmune disease market is a blue ocean, with new targets and mechanisms driving rapid industry development. The global autoimmune market reached $132.3 billion in 2022 and is expected to grow to $176.7 billion by 2030, with a CAGR of 3.68% [2][3] - The drug development paradigm is shifting from broad-spectrum anti-inflammatory treatments to precision regulation, with significant room for improvement in efficacy and safety of existing drugs [2][3] Group 2 - Psoriasis affects approximately 125 million patients globally, with a focus on large molecule antibody drugs and a surge in small molecule oral TYK2 inhibitors that may replace existing treatments [3] - Atopic dermatitis impacts over 204 million people worldwide, with Dupilumab achieving sales exceeding $12.9 billion in the first three quarters of 2025, and new oral drugs like STAT6PROTAC showing superior efficacy [3] - The clinical demand for autoimmune diseases remains largely unmet, with domestic companies actively innovating in drug development, focusing on target innovation and expanding indications [4] Group 3 - Companies to watch include: 1. **Xiansheng Pharmaceutical**: Focused on differentiated targets with potential candidates like SIM0278, SIM0709, and SIM0711 [4] 2. **Kangnuo Pharmaceutical**: Rapidly increasing sales of Dupilumab, with peak sales expected to reach 5 billion yuan; CM512 shows promise as a leading TSLPxIL-13 dual antibody [4] 3. **Quansheng Biotechnology**: QX013N targets c-kit for CSU treatment, with additional dual antibody projects expected to submit IND applications between 2025 and 2026 [4] 4. **Yifang Biotechnology**: D-2570 (TYK2 inhibitor) is in Phase II clinical trials for UC, with promising Phase II data for psoriasis [4] 5. **Sanofi Genzyme**: Rapidly advancing IL-5 monoclonal antibody for asthma, with NDA submission expected by 2027 [4]

Core Viewpoint - The article discusses the recent update of China's National Medical Insurance Drug List, which includes 114 new drugs, highlighting the introduction of a commercial health insurance innovative drug directory alongside the basic insurance list, aiming to enhance patient access to innovative treatments and address gaps in drug coverage [6][13]. Group 1: New Drugs in the National Medical Insurance Directory - A total of 114 new drugs have been added to the directory, covering various treatment areas including 36 for tumors, 12 for chronic diseases, and 10 for rare diseases, with the number of class 1 new drugs increasing from 38 to 50, setting a new historical high [6][7]. - Notable "star drugs" include LuKangsa Tazhu (for tumors), Fluorazirase tablets, and Spilumab (for specific dermatitis), which will benefit a wide range of patients, including those with triple-negative breast cancer and chronic sinusitis [7][8]. Group 2: Financial Impact on Patients - The average price reduction for negotiated drugs has historically been around 60%, with 112 out of 127 drugs successfully negotiated this year, resulting in significant cost savings for patients [9]. - The introduction of Spilumab, priced at around 1,000 yuan per injection, is expected to significantly lower the financial burden on patients, making innovative treatments more accessible [9]. Group 3: Implementation Challenges - There are concerns regarding the "last mile" issue in drug availability at hospitals, as many negotiated drugs are still provided through external pharmacies, and hospitals may hesitate to prescribe these due to cost concerns [10][11]. - The new regulations require that hospitals must not limit the availability of negotiated drugs based on overall budget constraints, ensuring that these drugs are accessible to patients [11]. Group 4: Changes in the Drug Directory - This year, 29 drugs were removed from the directory due to being replaced or not produced, with a total of 467 drugs removed over the past eight years for similar reasons [12]. - A six-month transition period has been established for patients using drugs that are not renewed in the directory, ensuring continuity of care [12]. Group 5: Commercial Health Insurance Innovative Drug Directory - The newly established commercial health insurance innovative drug directory includes 19 drugs, focusing on high-value innovative treatments that cannot be covered by the basic insurance directory [13][15]. - The drugs in this directory are characterized by high innovation, significant clinical value, and the need for diverse payment options, with 50% being class 1 new drugs [15]. Group 6: Benefits for Patients - The commercial health insurance directory aims to provide a curated list of high-quality drugs, reducing the selection burden for insurance companies and potentially lowering costs for patients through reduced premiums or increased reimbursement rates [16]. - The integration of the commercial insurance directory with existing medical insurance systems is being explored to enhance patient experience and access to innovative treatments [16]. Group 7: Future Prospects and Challenges - The implementation of the commercial health insurance innovative drug directory is dependent on market mechanisms, with insurance companies determining the usage and timing of these drugs [19]. - Emphasis on actuarial pricing and collaboration between insurance companies and pharmaceutical firms is crucial for the sustainable rollout of these innovative drugs [19].